Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
相关临床试验
7
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2015
进行中（未招募）
2
28.6%
已完成
1
14.3%
招募中
2
28.6%
终止
2
28.6%
暂无批准数据
- Dianthus Therapeutics receives a Hold rating from a Seeking Alpha analyst, reflecting a balanced view of the company's near-term prospects and pipeline trajectory. - A competitor's C1s-targeting program experienced a setback in chronic inflammatory demyelinating polyneuropathy (CIDP), reshaping the competitive landscape for complement-directed therapies. - Dianthus continues to advance claseprubart, its lead complement inhibitor candidate, which remains the central driver of the company's clinical and investment outlook.
- Oorja Bio emerges as a clinical-stage company with $30 million Series A funding from Westlake BioPartners to develop ORJ-001, a first-in-class peptide therapy for idiopathic pulmonary fibrosis. - ORJ-001 represents a novel therapeutic approach targeting alveolar epithelial type 2 cells to restore lung function and reverse fibrosis, with Phase 2 trials planned for 2026. - The company is led by experienced executives who previously developed sotatercept at Acceleron Pharma, bringing proven expertise in pulmonary drug development. - Preclinical studies demonstrated ORJ-001's ability to reverse established fibrosis and regenerate normal lung morphology in validated animal models of pulmonary fibrosis.
- Dianthus Therapeutics will present interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial evaluating claseprubart in chronic inflammatory demyelinating polyneuropathy. - The company has scheduled a conference call and webcast for March 9, 2026 to discuss the clinical data from this pivotal trial. - Claseprubart represents a next-generation therapy being developed to transform treatment of severe autoimmune diseases including CIDP.
- Leads Biolabs and Dianthus Therapeutics have successfully dosed the first subject in a Phase 1 trial of LBL-047 (DNTH212), a bifunctional fusion protein targeting both innate and adaptive immune pathways in autoimmune diseases. - The investigational therapy simultaneously targets plasmacytoid dendritic cells to reduce Type 1 interferon production while inhibiting BAFF/APRIL pathways to suppress B-cell function, potentially addressing limitations of single-target therapies. - The two-part Phase 1 trial will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers and systemic lupus erythematosus patients, with top-line results expected in the second half of 2026. - LBL-047 has been optimized for patient-friendly subcutaneous self-administration with quarterly or less frequent dosing, positioning it as a potential first-line biologic therapy for multiple autoimmune disorders.
- Dianthus Therapeutics has entered an exclusive licensing agreement with Leads Biolabs for DNTH212, a bifunctional fusion protein that simultaneously targets BDCA2 and BAFF/APRIL pathways to address severe autoimmune diseases. - The investigational therapy demonstrated superior performance compared to existing treatments, showing better plasmacytoid dendritic cell depletion than litifilimab and superior immunoglobulin reduction versus povetacicept in preclinical studies. - DNTH212 has received FDA IND clearance and is expected to enter Phase 1 trials in Q4 2025, with the licensing deal valued at up to $1 billion in total milestone payments. - The agreement positions Dianthus with approximately $525 million in pro forma cash and extends their financial runway into 2028 while advancing a potentially first-in-class autoimmune treatment.
- Dianthus Therapeutics' shares climbed approximately 50% following the Monday release of positive Phase 2 data for claseprubart in generalized myasthenia gravis. - The drug demonstrated statistically significant and clinically meaningful improvements in patient symptoms after 13 weeks of treatment at two different dose levels. - The positive results position Dianthus as a contender in the large and growing myasthenia gravis drug market while derisking studies in other conditions. - The company quickly capitalized on the momentum by raising $251 million in a stock offering on Tuesday following the data release.
- Dianthus Therapeutics successfully closed an upsized $288 million underwritten public offering, nearly doubling the initially proposed $150 million raise to fund its complement therapeutics development. - The biotechnology company sold 7.6 million shares at $33.00 per share plus pre-funded warrants, with underwriters fully exercising their option to purchase additional shares. - Proceeds will advance the company's preclinical and clinical development activities for next-generation antibody complement therapeutics targeting severe autoimmune diseases. - The funding supports development of claseprubart and other monoclonal antibody candidates designed with improved selectivity and potency for autoimmune and inflammatory conditions.
- Dianthus Therapeutics' claseprubart demonstrated statistically significant and clinically meaningful improvements compared to placebo in a Phase 2 trial for generalized myasthenia gravis. - The drug showed efficacy benefits comparable to AstraZeneca's blockbuster treatments Ultomiris and Soliris, which generate over $2 billion annually for the same indication. - Safety concerns emerged regarding anti-nuclear antibodies in the high-dose arm, though the drug showed no treatment-related serious bacterial infections or clinical symptoms of autoimmune disorders. - The company plans to advance to Phase 3 trials next year and offers potential convenience advantages with home-administered self-injection delivery.
- Commit Biologics has established a Scientific Advisory Board co-chaired by antibody expert Janine Schuurman and CEO Mikkel Wandahl Pedersen to guide development of its BiCE™ complement activation platform. - The board includes five industry veterans with expertise in molecular biology, immunology, and antibody research, including former executives from Genmab, Regeneron, and Novo Nordisk. - The BiCE™ technology platform aims to harness the largely untapped complement system to selectively kill target cells in autoimmune diseases and cancer through enhanced C1q engagement. - This strategic move positions Commit to accelerate development of first-in-class complement engager therapeutics by leveraging decades of combined industry experience from the advisory members.
- Dianthus Therapeutics has successfully enrolled 65 patients in its Phase 2 MaGic trial of DNTH103 for generalized Myasthenia Gravis, exceeding the target of 60 patients with top-line results expected in September 2025. - DNTH103 is a monoclonal antibody designed to selectively inhibit the classical complement pathway by targeting the C1s protein, potentially offering patients a convenient self-administered subcutaneous injection dosed once every two weeks. - The company is building a neuromuscular franchise with DNTH103, which is also being evaluated in Phase 3 trials for Chronic Inflammatory Demyelinating Polyneuropathy and Phase 2 trials for Multifocal Motor Neuropathy, with results expected in the second half of 2026.
